Crohn's Disease (CD) Drug Development

The aim of therapy in Crohn's disease (CD) is the induction and maintenance of remission, promotion of mucosal healing, and restoration of quality of life. However, the best treatment method (combinations of biologics and immunomodulators) also lacks durable efficacy and has side effects. Therefore, the development of new therapies is imperative. Creative Biolabs is experienced in drug development. We provide a range of services of antibody development and cell-based therapy to support the drug development for CD.

Introduction to Crohn's Disease (CD)

CD is a chronic relapsing, remitting inflammatory disease of the gastrointestinal (GI) tract. Some patients may have continuously clinically active disease. The disease affects the GI tract discontinuously from mouth to anus, but most commonly the disease is located both in the ileum and colon (approximately 40%). It occurs in all ages with a higher incidence in the younger population and there is no marked sex difference. Recent epidemiological studies have found increased mortality risk in patients with severe CD.

Dynamic contrast-enhanced perfusion MRI images of active Crohn’s disease. Fig.1 Dynamic contrast-enhanced perfusion MRI images of active Crohn's disease. (Lee, 2020)

Treatment of CD

Mesenchymal stromal cells (MSCs) are a subset of non-hematopoietic stem cells that home to sites of inflammation where they exert potent immunomodulatory effects and contribute to tissue repair. Their utility is being explored in several inflammatory and immune-mediated disorders including CD, where they have demonstrated favorable safety, feasibility, and efficacy profiles.

There is an FDA-approved humanized monoclonal antibody and it is well tolerated in patients with CD. This monoclonal antibody is also effective for treating CD. A study showed that CD patients with previous anti-tumor necrosis factor (TNF) failure (failure or intolerance) have suggested that remission may be achieved beyond the 6-week period of treatment. At present, it has been approved by the European medicines agency (EMA) for the treatment of adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist.

Our Drug Development Services

CD brings great pain to patients and makes their life very inconvenient. As a pioneer in the drug research and development industry, Creative Biolabs has the responsibility and obligation to provide the most professional services of therapeutic antibody and cell therapy. We can provide you with the best services, including but not limited to:

  • Monoclonal Antibody Development for CD
  • Bispecific Antibody Development for CD
  • Cell-based Therapy for CD

Creative Biolabs has engaged more than 10 years in the field of drug research and development, which makes us get high reputation all over the world. If you want to enjoy the highest quality CD drug development services, please ask an expert for a specific consultation on your project.

Reference

  1. Lee, S.; et al. Quantitative evaluation of Crohn's disease using dynamic contrast-enhanced MRI in children and young adults. European Radiology. 2020, 30(6).

For Research Use Only | Not For Clinical Use



Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases

Contact us

USA

  • Location:

  • Call:

  • Fax:

  • Email:

UK

  • Location:

  • Call:

  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2022 Creative Biolabs. All Rights Reserved.